S100A2 and familial pancreatic carcinoma: S100A2, which involves a number of cellular processes such as cell cycle progression and differentiation, was dysregulated in lung, gastric, esophageal, ovarian, bladder, breast, thyroid, melanoma and pancreatic cancer [31].